Global Aminoglycosides Market – Industry Trends and Forecast to 2030

Aminoglycosides Market Analysis and Size

Aminoglycosides are highly potent antibiotics having numerous properties for the treatment of life-threatening infections. In humans and animals, the high usage of aminoglycosides in the treatment of different bacterial infections is growing because of the presence of characteristics such as bactericidal activity against staphylococci and certain mycobacteria. Among the drug segment gentamicin accounted for largest market share and it is expected to maintain its dominance during the forecast period. It is used to treat severe infections caused by bacteria, such as infections of the lungs, bones, joints, blood, skin, and urinary tract and meningitis.

Data Bridge Market Research analyses a growth rate in the aminoglycosides market in the forecast period 2023-2030. The expected CAGR of the aminoglycosides market tends to be around 4% in the mentioned forecast period. The market was valued at USD 1.68 million in 2022 and would grow to USD 2.30 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Aminoglycosides Market Scope and Segmentation

Market Definition

Aminoglycosides is the type of medicinal drug classified under bacteriologic gram-negative antibacterial agents and has a major function for restraining protein synthesis. Aminoglycosides consist of a part of the molecule known as amino-adjusted glycoside that is a sugar. It has been used to treat numerous bacterial infections of abdomen and urinary tract, bacteremia and endocarditis and others in humans as well as animals.

Global Aminoglycosides Market Dynamics

Drivers

• Increase in Tuberculosis Cases

The growing burden of tuberculosis is projected to drive the demand for aminoglycosides, particularly in low-income countries where the occurrence is alarmingly high and there is an urgent need for aminoglycosides. For instance, according to WHO 2021 update, a total of 1.5 million people died from tuberculosis in 2020 which includes 214,000 people with HIV. COVID-19 is the second most lethal infectious disease, while tuberculosis is the 13th most common cause of death worldwide.

• Increasing demand for Gentamicin

As per the research article published in 2020 under the title ‘Epidemiology of urological infections: a global burden’, urinary tract infections were among the most frequent infections in clinical practice. The huge burden of urinary tract infections is projected to increase the use of Gentamicin over the forecast period. Gentamicin forms the first line of treatment for several diseases. The usage of Gentamicin is predominantly high in developing regions where it is cost-effective and productive drug for several infectious diseases.

Opportunities

• Rising Adoption Of Injectable and Oral Drugs

Injectable administration is accounted for the largest share. This route is recommended for human medical usage as it provides the optimum mode of drug action mechanism through intravenous or intramuscular route for treatment. Oral use of aminoglycoside antibiotics is generally for bowel surgery to prevent severe infection at the time of surgery. Thus, this feasible route of administration increases the market share.

• Increasing Launch of New Drugs

The rising launch of several new drugs used for the treatment of bacterial infections create opportunities for the market growth. For instance, in November 2020, Huvepharma Inc. launched AVERT NE, a novel new vaccination designed to help manage necrotic enteritis caused by Clostridium perfringens Type A. Curtiss Healthcare, Inc.'s exclusive and proprietary transgenic attenuated Salmonella vaccine (RASV) technology is used as the delivery platform for AvertNE to produce an autoimmune reaction and prevent hens from necrotic enteritis.

 Restraints/Challenges

• Side Effects of Chemotherapy

Several toxic effects associated with these drugs, such as muscle twitching, seizure, and irreversible hearing loss, are responsible for restrictive growth in this industry.

• Long Approval Delays of Drugs

Short provision of quality assured active pharmaceutical ingredient and WHO-GMP compliant product for capreomycin and kanamycin acts as a primary factor which leads in failure of pre-qualification of these drug thus limiting sector growth in more developed countries.

This aminoglycosides market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the aminoglycosides market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Aminoglycosides Market

The COVID-19 outbreak significantly impacted the healthcare sector. According to the article published in 2021 under the title ‘Aminoglycosides as potential inhibitors of SARS-CoV-2 main protease: an in silico drug repurposing study on FDA-approved antiviral and anti-infection agents’, aminoglycosides were likely to be used as a base to create powerful COVID-19 medicinal compounds. According to a study published in August 2020 titled ‘Studies highlight the dynamic impact of COVID-19 on antibiotic use’, more than 1,700 hospitalized COVID-19 patients were treated at 38 Michigan hospitals in the U.S. from March 13, 2020, to June 18, 2020, many of them received early antibiotic therapy, with antibiotic use as high as 84% in some hospitals, that showed a positive impact on the market growth. Henceforth, as per the factors mentioned above, COVID-19 significantly impacted the market.

Recent Developments

• In March 2022, Padagis received the U.S. FDA approval for its AB-rated generic version of Tobradex Ophthalmic Suspension. The solution contains active ingredients such as tobramycin and dexamethasone. Tobradex Ophthalmic Suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.

Global Aminoglycosides Market Scope

The aminoglycosides market is segmented on the basis of drug, application, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug

• Neomycin
• Gentamicin
• Kanamycin
• Other

Application

• Veterinary
• Skin Infection
• Respiratory Diseases
• UTI and Pelvic Diseases
• Other Diseases

Route of Administration

• Injectable
• Topic
• Oral
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Aminoglycosides Market Regional Analysis/Insights

The aminoglycosides market is analyzed and market size insights and trends are provided by drug, application, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the aminoglycosides market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing positive growth for the aminoglycosides market throughout the forecasted period due to increased new research and developments on aminoglycosides markets.

North America dominates the market due to the presence of key manufacturers of the product is high and, increasing research and development activities, healthcare expenditure.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Global Aminoglycosides Market Share Analysis

The aminoglycosides market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to aminoglycosides market.

Key players operating in the aminoglycosides market include:

• Kremoint Pharma Pvt. Ltd. (India)
• HuvePharma (Bulgaria)
• Medison Pharma (India)
• Medico Remedies Ltd (India)
• Zoetis (U.S.)
• Pfizer Inc (U.S.)
• AstraZeneca (U.K.)
• AbbVie Inc. (U.S.)
• Teva Pharmaceutical Industries (Israel)

SKU-57138